Abstract
IntroductionAmong white people, the incidence of cutaneous malignant melanoma (CMM) has been increasing steadily for several decades. Meanwhile, there has also been a significant improvement in 5-year survival among patients with melanoma. This population-based cohort study investigates the five-year melanoma-specific survival (MSS) for all melanoma cases recorded in 2015 in the Veneto Tumor Registry (North-Est Italian Region), taking both demographic and clinical-pathological variables into consideration.MethodsThe cumulative melanoma-specific survival probabilities were calculated with the Kaplan-Meier method, applying different sociodemographic and clinical-pathological variables. Cox’s proportional hazards model was fitted to the data to assess the association between independent variables and MSS, and also overall survival (OS), calculating the hazard ratios (HR) relative to a reference condition, and adjusting for sex, age, site of tumor, histotype, melanoma ulceration, mitotic count, tumor-infiltrating lymphocytes (TIL), and stage at diagnosis.ResultsCompared with stage I melanoma, the risk of death was increased for stage II (HR 3.31, 95% CI: 0.94-11.76, p=0.064), almost ten times higher for stage III (HR 10.51, 95% CI: 3.16-35.02, p<0.001), and more than a hundred times higher for stage IV (HR 117.17, 95% CI: 25.30-542.62, p<0.001). Among the other variables included in the model, the presence of mitoses and histological subtype emerged as independent risk factors for death.ConclusionsThe multivariable analysis disclosed that older age, tumor site, histotype, mitotic count, and tumor stage were independently associated with a higher risk of death. Data on survival by clinical and morphological characteristics could be useful in modelling, planning, and managing the most appropriate treatment and follow-up for patients with CMM.
Highlights
Among white people, the incidence of cutaneous malignant melanoma (CMM) has been increasing steadily for several decades
The present study investigates the five-year melanomaspecific survival (MSS) for all cases of CMM recorded in 2015 in the resident population of a north-eastern Italian region (Veneto)
The 5-year overall survival (OS) was 83.8% and it was higher for females (86.6%; 95% CI: 84.0, 89.4) than for males (81.2%; 95% CI: 78.4, 84.2)
Summary
The incidence of cutaneous malignant melanoma (CMM) has been increasing steadily for several decades. A significant improvement in CMM patients’ 5-year overall survival has been reported, and related mostly to the increasing prevalence of cancers detected in their earliest, “thinner” stage” [3, 4]. Both the rising incidence of CMM (all stages), and changes in the treatment panorama ( including the advent of targeted therapies) prompt the collection of updated information which might re-orient both prevention efforts and diagnostic/therapeutic strategies. Based on the natural history of CMM, a well-established set of clinicopathological variables has been significantly correlated with the clinical outcome of melanoma patients These data are often inconsistently recorded and/or scattered over different digital archives. This situation interferes with efforts to validate prognostic variables in the “real world” of large-scale population-based studies
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
